Literature DB >> 23193095

Prophylactic penicillin after 5 years of age in patients with sickle cell disease: a survey of sickle cell disease experts.

Timothy L McCavit1, Megan Gilbert, George R Buchanan.   

Abstract

BACKGROUND: Since the publication of the Prophlyactic Penicillin Study II in 1995, the management of penicillin prophylaxis for children with sickle cell disease (SCD) after 5 years of age has been controversial. In this study, we sought to describe current practice patterns of pediatric hematologists related to cessation of penicillin prophylaxis for children with SCD after 5 years of age. PROCEDURE: We performed a cross-sectional, electronic survey of pediatric hematologists with expertise in SCD to examine practices regarding penicillin prophylaxis in children with SCD after 5 years of age. We also investigated factors potentially associated with continuation of penicillin prophylaxis using the Jonckheere-Terpstra test and Fisher's exact test.
RESULTS: Of the 106 physicians surveyed from 76 centers, 84% completed the survey. Among respondents, 76% routinely recommended cessation of penicillin prophylaxis after 5 years of age. The practice of routinely continuing penicillin after 5 years of age was associated with decreased concern about antibiotic resistance in Streptococcus pneumoniae (P = 0.01), with the usage of prophylactic penicillin in mild SCD genotypes (sickle hemoglobin-C disease and sickle β(+) thalassemia, P = <0.001), and with increasing use of other preventive evaluations (e.g., MRI for silent stroke) in childhood (P = 0.05).
CONCLUSION: Most pediatric hematologists with an SCD expertise recommend cessation of prophylactic penicillin after 5 years of age.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23193095     DOI: 10.1002/pbc.24395

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

Review 1.  Pediatric sickle cell disease: past successes and future challenges.

Authors:  Emily Riehm Meier; Angeli Rampersad
Journal:  Pediatr Res       Date:  2016-10-05       Impact factor: 3.756

2.  Strategies to increase access to basic sickle cell disease care in low- and middle-income countries.

Authors:  Meghna Dua; Halima Bello-Manga; Yvonne M Carroll; Aisha Amal Galadanci; Umma Abdulsalam Ibrahim; Allison A King; Ayobami Olanrewaju; Jeremie H Estepp
Journal:  Expert Rev Hematol       Date:  2022-04-12       Impact factor: 2.819

3.  Assessing the Immunogenic Response of a Single Center's Pneumococcal Vaccination Protocol in Sickle Cell Disease.

Authors:  Jonathan D Santoro; Leann Myers; Julie Kanter
Journal:  J Pediatr Hematol Oncol       Date:  2016-04       Impact factor: 1.289

Review 4.  Travelers with sickle cell disease.

Authors:  Shaina M Willen; Courtney D Thornburg; Paul M Lantos
Journal:  J Travel Med       Date:  2014-06-19       Impact factor: 8.490

Review 5.  Convergence of Inflammatory Pathways in Allergic Asthma and Sickle Cell Disease.

Authors:  Amali E Samarasinghe; Jason W Rosch
Journal:  Front Immunol       Date:  2020-01-24       Impact factor: 7.561

Review 6.  Life-Threatening Infectious Complications in Sickle Cell Disease: A Concise Narrative Review.

Authors:  Dominik Ochocinski; Mansi Dalal; L Vandy Black; Silvana Carr; Judy Lew; Kevin Sullivan; Niranjan Kissoon
Journal:  Front Pediatr       Date:  2020-02-20       Impact factor: 3.418

7.  Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease.

Authors:  Mahvish Q Rahim; Alexandria M Arends; Seethal A Jacob
Journal:  J Pediatr Hematol Oncol       Date:  2022-01-01       Impact factor: 1.289

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.